Dave Coulier was diagnosed with Stage 3 non-Hodgkin lymphoma, a type of blood cancer that starts in the lymphatic system.

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19 ... Second Cancers Related to CAR-T Therapy June 12, 2024 — A new detailed ...

It’s more common in older adults, people with weakened immune systems, and people with primary CNS lymphoma. There are two main types of lymphocytes, called B cells and T cells. But the kind ...

LUND, SE / ACCESS Newswire / March 20, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...

LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

T-cell lymphoma is a rare cancer that develops in ... Median progression free survival (PFS) was 6.2 months. Additionally, the drug candidate was well tolerated with no new safety signals.

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...